Lv4
434 积分 2022-10-31 加入
The right dose, not the highest dose: rethinking obesity pharmacotherapy
4天前
已完结
Amping Up Receptor Balance and Bias: Fine Tuning of Unimolecular Multiagonists
7天前
已完结
A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice
10天前
已完结
Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity
10天前
已完结
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
30天前
已完结
Pericardial effusions and sotatercept therapy in pulmonary arterial hypertension: a multicentre, real-world experience
1个月前
已完结
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
1个月前
已完结
Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial
1个月前
已完结
Treatment of sporadic inclusion body myositis with bimagrumab
1个月前
已完结
Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis
1个月前
已完结